Khanna and co-workers aimed to investigate if metformin use reduces the odds of developing new neovascular AMD (nAMD). This is a case–control study of 86,930 subjects with new diagnoses of nAMD and 86,918 matched control subjects. Metformin use was associated with reduced odds ratio of developing nAMD (odds ratio 0.95, 95% confidence interval 0.91–0.98) in full sample and diabetic cohort particularly in patients without any diabetic retinopathy. The protective effect was noted for 24-month cumulative doses below 1,080 g in diabetic subjects without diabetic retinopathy. They concluded that metformin may be able to be repurposed as a pharmacologic preventative agent for nAMD.
Khanna S, Shaw L, Hyman MJ, et al. Associatıon of Metformin Use With Risk of Newly Onset Neovascular Age-Related Macular Degeneration Development. Retina. 2024;44(2):205-213. https://pubmed.ncbi.nlm.nih.gov/38259182/
